An Erratum on
Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma
by Dong T, Zhang B, Zhang R, Wang C, Liu X, Wang F, Hao N, Tan K, and Chang Y-Z (2022) 12:963096. doi: 10.3389/fonc.2022.963096
Due to a production error, there was an error in affiliation 1. Instead of “Key Laboratory of Molecular and Cellular Biology of Ministry of Education, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Shijiazhuang, China”, it should be “Key Laboratory of Molecular and Cellular Biology of Ministry of Education, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Hebei Normal University, Shijiazhuang, China”.
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: hepcidin, glioma, prognostic biomarker, immune cell infiltration, iron
Citation: Frontiers Production Office (2022) Erratum: Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. Front. Oncol. 12:1085757. doi: 10.3389/fonc.2022.1085757
Received: 31 October 2022; Accepted: 25 November 2022;
Published: 06 December 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org